Although decreased BDNF levels are well recognized in the brain of AD patients and in animal models [38–41], at present, no medicine targeting BDNF or its receptor, TrkB, has been clinically shown to exert precise anti-AD effects, which may be due to difficulties related to entry of the drugs into the brain and their short half-life. The gene discussed is NTRK2; the disease is Alzheimer disease.